CRB-701 / Corbus Pharma, CSPC Pharma 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CRB-701 / CSPC Pharma, Corbus Pharma
CRB-701-01, NCT06265727: A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Recruiting
1/2
420
Europe, US, RoW
CRB-701
Corbus Pharmaceuticals Inc., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Solid Tumor, Adult
01/27
01/27
SYS6002-001, CTR20222932: An open-label, single-arm, multicenter phase I clinical trial evaluating the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of SYS6002 in patients with advanced solid tumors

Recruiting
1
380
China
CRB-701 - CSPC Pharma, Corbus Pharma
CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd
Advanced solid tumors
 
 
ChiCTR2200066256: Phase I, Dose Escalation, PK Expansion and Cohort Expansion study of SYS6002 in Patients with Advanced Solid Tumors

Not yet recruiting
1
366
 
SYS6002
Fudan University Shanghai Cancer Center; CSPC Megalith Biopharmaceutical Co., Ltd.., CSPC Megalith Biopharmaceutical Co., Ltd..
Advanced Solid Tumors
 
 

Download Options